California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

Social proof—seeing peers safely participate—reduces fear and builds trust in clinical trials. Sharing real stories and ...

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...